Matinas BioPharma Holdings, Inc. (MTNB): Nasdaq/NYSE listing notice — Matinas BioPharma receives NYSE American delisting notice for low equity

Matinas BioPharma Holdings, Inc.

Stockholders' equity was $4.83M as of Dec 31, 2025, below the $6M threshold for five years of losses.
Company has until May 2, 2026 to submit a plan to regain compliance; cure period up to 18 months.
Independent auditor included a going-concern paragraph in the 10-K for the year ended Dec 31, 2025.
No immediate impact on listing; common stock continues trading on NYSE American pending review.
If plan is rejected, delisting proceedings will commence; company may appeal per NYSE rules.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Matinas BioPharma Holdings, Inc. received a nyse_american deficiency notice notice regarding stockholders equity (rules 1003(a)(i), 1003(a)(ii), 1003(a)(iii)).

Exchange: nyse american
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 1003(a)(i), 1003(a)(ii), 1003(a)(iii)

Exact text from the filing

April 2, 2026, Matinas BioPharma Holdings, Inc. (the “Company”) received a written notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) indicating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the “Company Guide”) requiring a company to have stockholders’ equity of at least $2.0 million if it has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years, Section 1003(a)(ii) of the Company Guide requiring a company to ha

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Matinas BioPharma Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-015170

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.